Current Status of Biosimilars in Oncology

@article{Camacho2017CurrentSO,
  title={Current Status of Biosimilars in Oncology},
  author={Luis H Camacho},
  journal={Drugs},
  year={2017},
  volume={77},
  pages={985-997}
}
Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach approximately US$68 billion at that time. Approximately 20 biosimilars have entered the European market since the launch of the original approval guidelines in 2005, and four biosimilars have been… CONTINUE READING